Spartan Capital Securities, LLC Raises $5 Million for Lixte Biotechnology Holdings, Inc: Focus on Cancer Therapies

Spartan Capital Securities, LLC helped raise $5.0 million in a private placement for Lixte Biotechnology Holdings, Inc. The offering included Common Stock, Series B Convertible Preferred Stock, and Common Warrants to accredited investors. Lixte plans to use the funds for general corporate purposes and working capital. Spartan Capital praised Lixte’s commitment to advancing innovative oncology therapies. The securities sold were not registered and may not be offered in the U.S. without proper registration. For more information, visit the SEC’s website. Lixte is focused on developing cancer therapies based on novel biological pathways, with promising trials for various cancers.

Read more at GlobeNewswire: Spartan Capital Securities, LLC Serves as Placement Agent